Cross-cohort heterogeneity encountered while validating a model for HIV disease progression among antiretroviral initiators

Journal of Clinical Epidemiology

Volumn 62, Issue 7, 2009, Pages 729-737

  Shepherd, Bryan E ^a   Sterling, Timothy R ^a   Moore, Richard D ^b   Raffanti, Stephen P ^a   Hulgan, Todd ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; Antiretroviral therapy; Bootstrap; CD4 lymphocyte percent; Heterogeneity; Loss to follow up; Validation

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MODEL; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; EPIDEMIOLOGIC METHODS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PATIENT COMPLIANCE; PROGNOSIS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 67349156426     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2008.09.002     Document Type: Article

References (28)

1. Mellors J.W., Munoz A., Giorgi J.V., Margolick J.B., Tassoni C.J., Gupta P., et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126 (1997) 946-954
2. Egger M., May M., Chene G., Phillips A.N., Ledergerber B., Dabis F., et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360 (2002) 119-129
3. Gange S.J., Kitahata M.M., Saag M.S., Bangsberg D.R., Bosch R.J., Brooks J.T., et al. Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol 36 (2007) 294-301
4. McGowan C.C., Cahn P., Gotuzzo E., Padgett D., Pape J.W., Wolff M., et al. Cohort profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme. Int J Epidemiol 36 (2007) 969-976
5. Sterling T.R., Chaisson R.E., and Moore R.D. Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of >350 cells/mm3: disease progression, treatment durability, and drug toxicity. Clin Infect Dis 36 (2003) 812-815
6. Hogg R.S., Yip B., Chan K.J., Wood E., Craib K.J., O'Shaughnessy M.V.., et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 286 (2001) 2568-2577
7. Phillips A.N., Staszewski S., Weber R., Kirk O., Francioli P., Miller V., et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 286 (2001) 2560-2567
8. Sterling T.R., Chaisson R.E., Keruly J., and Moore R.D. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study. J Infect Dis 188 (2003) 1659-1665
9. Palella Jr. F.J., Deloria-Knoll M., Chmiel J.S., Moorman A.C., Wood K.C., Greenberg A.E., et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 138 (2003) 620-626
10. Opravil M., Ledergerber B., Furrer H., Hirschel B., Imhof A., Gallant S., et al. Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 × 10(6)/l. AIDS 16 (2002) 1371-1381
11. The Antiretroviral Therapy Cohort Collaboration. Rates of disease progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies. J Infect Dis 194 (2006) 612-622
12. Hulgan T., Shepherd B.E., Raffanti S.P., Fusco J.S., Beckerman R., Barkanic G., et al. Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected person initiating highly active antiretroviral therapy. J Infect Dis 195 (2007) 425-431
13. Becker S.L., Raffanti S.R., Hansen N.I., Fusco J.S., Fusco G.P., Slatko G.H., et al. Zidovudine and stavudine sequencing in HIV treatment planning: findings from the CHORUS HIV cohort. J Acquir Immune Defic Syndr 26 (2001) 72-81
14. Moore R.D. Understanding the clinical and economic outcomes of HIV therapy: the Johns Hopkins HIV clinical practice cohort. J Acquir Immune Defic Syndr Hum Retrovirol 17 Suppl. 1 (1998) S38-S41
15. Centers for Disease Control. 1993. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 41 RR-17 (1992) 1-19
16. Fusco GP, Justice AC, Becker SL, Raffanti SP, Coll-Erickson P, Fusco JS. Strategies for obtaining consistent diagnoses for cause of death in an HIV observational cohort study [#5584]. Presented at: XIV International AIDS Conference, 2002, Barcelona, Spain.
17. Grambsch P., and Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81 (1994) 515-526
18. Harrell F.E. Regression modeling strategies, with applications to linear models, logistic regression, and survival analysis (2001), Springer, New York
19. Harrell F.E., Lee K.L., and Mark D.B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15 (1996) 361-387
20. Shepherd B.E. The cost of checking proportional hazards. Stat Med 27 (2008) 1248-1260
21. Efron B. Estimating the error rate of a prediction rule: improvement on cross-validation. J Am Stat Assoc 78 (1983) 316-331
22. Efron B., and Tibshirani R. An introduction to the bootstrap (1993), Chapman & Hall, New York
23. Sterne JA, May MT, Sabin CA, Phillips AN, Costagliola D, Chene G, et al. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1 infected patients. J Acquir Immune Defic Syndr, in press.
24. Rosen S., Fox M.P., and Gill C.J. Patient retention in antiretroviral therapy programs in Sub-Saharan Africa: a systematic review. PLoS Med 4 10 (2007) e298
25. May M., Porter K., Sterne J.A., Royston P., and Egger M. Prognostic model for HIV-1 disease progression in patients starting antiretroviral therapy was validated using independent data. J Clin Epidemiol 58 (2005) 1033-1041
26. May M., Royston P., Egger M., Justice A.C., Sterne JA, and ART Cohort Collaboration. Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy. Stat Med 23 (2003) 2375-2398
27. Altman D.G., and Royston P. The cost of dichotomizing continuous variables. BMJ 332 (2006) 1080
28. Royston P., Altman D.G., and Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 25 (2006) 127-141